Sanctuary Advisors LLC Acquires Shares of 4,437 Vaxcyte, Inc. (NASDAQ:PCVX)

Sanctuary Advisors LLC bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 4,437 shares of the company’s stock, valued at approximately $507,000.

Several other institutional investors have also modified their holdings of PCVX. China Universal Asset Management Co. Ltd. increased its holdings in Vaxcyte by 68.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after purchasing an additional 8,685 shares during the last quarter. Natixis Advisors LLC grew its position in shares of Vaxcyte by 61.1% during the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock worth $2,594,000 after buying an additional 8,606 shares in the last quarter. Tri Locum Partners LP bought a new stake in shares of Vaxcyte in the second quarter worth $8,559,000. Hsbc Holdings PLC acquired a new stake in Vaxcyte in the second quarter valued at $1,053,000. Finally, Lisanti Capital Growth LLC boosted its stake in Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after acquiring an additional 13,175 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other news, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $92.25, for a total transaction of $218,263.50. Following the transaction, the chief executive officer now directly owns 136,215 shares of the company’s stock, valued at approximately $12,565,833.75. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. This represents a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 117,830 shares of company stock valued at $12,383,030 in the last ninety days. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Bank of America boosted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Mizuho upped their price target on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Jefferies Financial Group raised their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $145.71.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $85.91 on Thursday. The firm has a market capitalization of $10.71 billion, a P/E ratio of -18.68 and a beta of 0.94. The business has a 50 day simple moving average of $96.95 and a 200 day simple moving average of $92.58. Vaxcyte, Inc. has a 12-month low of $53.83 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the firm earned ($0.91) earnings per share. Research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.